

[Fomepizole](#)

Essential medicine status

Section:

[4. Antidotes and other substances used in poisonings](#) [4.2. Antidotes and other substances used in poisonings > Specific](#)

ATC codes: [V03AB34](#)

EMLc

Indication

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified ICD11 code: [NE61](#)

INN

Fomepizole

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate) ; 1 g per mL in 1.5 mL ampoule or vial (base)

EML status history

First added in 2013 ([TRS 985](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Fomepizole](#)

DrugBank

[Fomepizole](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.